These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35793110)
1. Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. Wang H; Xue W; Yan W; Yin L; Dong B; He B; Yu Y; Shi W; Zhou Z; Lin H; Zhou Y; Wang Y; Shi Z; Ren S; Gao X; Wang L; Xu C JAMA Surg; 2022 Aug; 157(8):693-700. PubMed ID: 35793110 [TBL] [Abstract][Full Text] [Related]
2. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial. Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911 [TBL] [Abstract][Full Text] [Related]
3. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial. Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293 [TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. de la Rosette J; Dominguez-Escrig J; Zhang K; Teoh J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke T; Ng CF; Leung CH; Sanchez-Salas R; Laguna P J Urol; 2023 Feb; 209(2):347-353. PubMed ID: 36441776 [TBL] [Abstract][Full Text] [Related]
6. A Multicenter Single-Arm Objective Performance Criteria Trial to Determine the Efficacy and Safety of High-Frequency Irreversible Electroporation as Primary Treatment for Localized Prostate Cancer: A Study Protocol. He BM; Xue W; Yan WG; Yin L; Dong BJ; Zhou ZE; Lin HZ; Zhou Y; Wang YQ; Shi ZK; Zhou H; Wang SD; Ren SC; Gao X; Wang LH; Xu CL; Wang HF Front Oncol; 2021; 11():760003. PubMed ID: 34858837 [TBL] [Abstract][Full Text] [Related]
12. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685 [TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167 [TBL] [Abstract][Full Text] [Related]
14. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
15. Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study). Sood A; Jeong W; Palma-Zamora I; Abdollah F; Butaney M; Corsi N; Wurst H; Arora S; Kachroo N; Hassan O; Gupta N; Gorin MA; Menon M Eur Urol; 2022 Apr; 81(4):396-406. PubMed ID: 34872786 [TBL] [Abstract][Full Text] [Related]
16. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721 [TBL] [Abstract][Full Text] [Related]
17. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844 [TBL] [Abstract][Full Text] [Related]
18. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580 [TBL] [Abstract][Full Text] [Related]
19. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy. Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]